Cian Healthcare Ltd
Fundamental Score
Cian Healthcare Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of CHCL across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Strong Cash Generation (₹32.96 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
12 factors identified
Below-Average Return on Equity (-14.27%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-5.70%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Profit Decline Concern (-20.75%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-38.98%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-11.55% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Elevated Debt Levels (D/E: 1.05)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Weak Interest Coverage (-133.33x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Low Promoter Commitment (27.11%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
High Share Pledging Risk (34.48%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Cian Healthcare Ltd
About CHCL
Business Overview
Cian Healthcare Limited engages in the research, development, manufacture, marketing, and sale of pharmaceutical products in India. It offers pharmaceutical products in various therapeutic areas of gynecology, haematinic, cardio- diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, and vitamins and nutrient products. The company also provides male and female infertility, reproductive wellness, energy boosting, autism, multivitamins, joint care products, and haematinic products, as well as face and hair serums, veterinary products, and cosmetics. It offers its products in the form of tablets, capsules, soft gels, liquid orals, ointments/ creams and sachets, and cosmetics. The company exports its products to various countries, such as Afghanistan, Benin, Bhutan, Bolivia, Cambodia, Sri Lanka, and Myanmar. The company was incorporated in 2003 and is based in Pune, India.
Company Details
Key Leadership
Latest News
CHCL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Cian Healthcare Ltd (CHCL)?
As of 20 Jan 2026, 10:58 am IST, Cian Healthcare Ltd (CHCL) is currently trading at ₹5.01. The stock has a market capitalization of ₹14.60 (Cr).
Is CHCL share price Overvalued or Undervalued?
CHCL is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Cian Healthcare Ltd share price?
Key factors influencing CHCL's price include its quarterly earnings growth (Sales Growth: -38.98%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Cian Healthcare Ltd a good stock for long-term investment?
Cian Healthcare Ltd shows a 5-year Profit Growth of N/A% and an ROE of -14.27%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.05 before investing.
How does Cian Healthcare Ltd compare with its industry peers?
Cian Healthcare Ltd competes with major peers in the Pharmaceuticals. Investors should compare CHCL's P/E of 0.00x and ROE of -14.27% against the industry averages to determine its competitive standing.
What is the P/E ratio of CHCL and what does it mean?
CHCL has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is CHCL performing according to Bull Run's analysis?
CHCL has a Bull Run fundamental score of N/A/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does CHCL belong to?
CHCL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Cian Healthcare Ltd.
What is Return on Equity (ROE) and why is it important for CHCL?
CHCL has an ROE of -14.27%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Cian Healthcare Ltd generates profits from shareholders' equity.
How is CHCL's debt-to-equity ratio and what does it indicate?
CHCL has a debt-to-equity ratio of 1.05, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is CHCL's dividend yield and is it a good dividend stock?
CHCL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has CHCL grown over the past 5 years?
CHCL has achieved 5-year growth rates of: Sales Growth -11.55%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in CHCL and why does it matter?
Promoters hold 27.11% of CHCL shares, with 34.48% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is CHCL's market capitalization category?
CHCL has a market capitalization of ₹15 crores, placing it in the Small-cap category.
How volatile is CHCL stock?
CHCL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for CHCL?
CHCL has a 52-week high of ₹N/A and low of ₹N/A.
What is CHCL's operating profit margin trend?
CHCL has a 5-year average Operating Profit Margin (OPM) of 9.63%, indicating the company's operational efficiency.
How is CHCL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -38.98% and YoY Profit Growth of -20.75%.
What is the institutional holding pattern in CHCL?
CHCL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.